tiprankstipranks
Trending News
More News >
Reinsurance Group (RGA)
NYSE:RGA

Reinsurance Group (RGA) AI Stock Analysis

Compare
358 Followers

Top Page

RGA

Reinsurance Group

(NYSE:RGA)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 5.2)
,
Outperform 73 (OpenAI - 5.2)
,
Outperform 73 (OpenAI - 5.2)
Rating:73Outperform
Price Target:
$224.00
▲(13.14% Upside)
Action:ReiteratedDate:03/20/26
The score is driven primarily by solid financial performance (growth, improved profitability, and strengthening leverage) and a strong earnings-call outlook with clear medium-term targets and capital return plans. Valuation is supportive at a modest P/E with a dividend. These positives are tempered by weaker short-term technical momentum and the inherent volatility highlighted in margins, cash flows, and certain near-term operating items.
Positive Factors
Strengthened balance sheet
RGA’s material equity build and lower leverage increase solvency headroom and capacity to underwrite risk long term. Stronger capital supports regulatory ratios, larger treaty limits, and optionality to deploy capital into blocks or buybacks without pressuring financial flexibility.
Consistent high ROE and record earnings
Sustained ROE above targets and record EPS indicate disciplined underwriting and investment returns. Persistent above-target profitability signals competitive pricing and capital efficiency that can compound returns and support capital returns and reinvestment over multiple years.
Growing in-force value and premium momentum
Material increases in value of in-force and steady premium growth show durable business expansion and product demand across regions. Rising in-force value supports future fee and spread income, underwriting leverage, and long-term earnings visibility from recurring treaty cash flows.
Negative Factors
Volatile cash flows
Material year-to-year swings in operating and free cash flow reduce predictability of capital deployment and shareholder returns. For a reinsurer, lumpy cash generation complicates timing of in-force purchases, retrocession decisions and sustained buybacks without raising leverage.
Biometric claims and U.S. group health exit
Adverse biometric experience and the strategic exit from U.S. group health remove a premium stream and highlight underwriting risk concentration. These developments can depress near-term earnings and underscore the need for disciplined repricing across products to avoid recurring loss volatility.
Execution dependence on capital deployment and investment income
Medium-term EPS targets rely on continued capital deployment, successful block transactions, and modest variable investment income. Execution, timing and market conditions for such transactions create structural execution risk that could widen earnings variability if deployments or investment returns underperform assumptions.

Reinsurance Group (RGA) vs. SPDR S&P 500 ETF (SPY)

Reinsurance Group Business Overview & Revenue Model

Company DescriptionReinsurance Group of America, Incorporated engages in reinsurance business. It offers individual and group life and health insurance products, such as term life, credit life, universal life, whole life, group life and health, joint and last survivor insurance, critical illness, disability, and longevity products; asset-intensive and financial reinsurance products; and other capital motivated solutions. The company also provides reinsurance for mortality, morbidity, lapse, and investment-related risk associated with products; and reinsurance for investment-related risks. In addition, it develops and markets technology solutions; and provides consulting and outsourcing solutions for the insurance and reinsurance industries. The company serves life insurance companies in the United States, Latin America, Canada, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Reinsurance Group of America, Incorporated was founded in 1973 and is headquartered in Chesterfield, Missouri.
How the Company Makes MoneyRGA makes money primarily by assuming insurance risk from primary insurers in exchange for premiums and other consideration, and then managing the difference between the income it receives and the claims and benefits it ultimately pays. Key revenue and earnings drivers include: (1) Reinsurance premiums and related fees: RGA enters into treaties (e.g., yearly renewable term, coinsurance, and other structures) where insurers cede a portion of their policies or risks to RGA. RGA receives periodic premiums (or allowances/consideration structured under the treaty) for providing this coverage and services such as underwriting support, product design input, and administrative capabilities where applicable. (2) Investment income on invested assets: Like other reinsurers, RGA invests the assets backing its obligations (from premiums and other treaty cash flows) and earns interest and other investment returns. Investment income is a significant contributor to profitability because liabilities are typically paid over time, allowing assets to be invested. (3) Risk margin/underwriting profit: RGA’s core profit comes from pricing and managing mortality, morbidity, and longevity risks such that, over time, premiums and fees plus investment income exceed claims, benefits, and operating costs. Actual results depend on experience (e.g., deaths, disability/health claims, lapses) versus assumptions, as well as reinsurance pricing discipline and portfolio mix. (4) Financial solutions and capital-motivated transactions: RGA also earns income through transactions designed to help insurers manage reserves, capital, and balance-sheet objectives (often involving coinsurance or other structures). Economics can include margins embedded in treaty cash flows and returns generated from investing associated assets, with profitability influenced by transaction structure, cost of capital, and experience on the underlying risks. (5) Retrocession and risk management: RGA may cede portions of its assumed risk to other reinsurers (retrocession) to manage concentration and volatility. While retrocession is typically a cost, it can support steadier earnings and capital efficiency, indirectly affecting profitability. (6) Other service-related income tied to reinsurance: To the extent RGA provides ancillary services connected to its reinsurance relationships (e.g., underwriting or risk analytics support), related fees may contribute, but details and materiality vary by contract and are not always separately disclosed. Overall, RGA’s earnings are driven by the scale and mix of reinsurance it writes, the spread between investment returns and the cost of liabilities, and how actual insured experience compares with pricing assumptions, alongside disciplined capital management and risk transfer strategies.

Reinsurance Group Earnings Call Summary

Earnings Call Date:Feb 05, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call emphasized multiple strong operational and financial accomplishments — record EPS, ROE above target, significant increase in value of in-force business, strong regional growth (APAC +18%, EMEA +35%), successful capital deployment ($2.5B in 2025), and resumed share repurchases — while acknowledging discrete challenges, notably unfavorable Q4 biometric claims largely tied to U.S. group health and a strategic exit from group health lines. Management reiterated solid capital positions (excess capital $2.7B), clear intermediate-term targets (8%–10% EPS growth, 13%–15% ROE) and a reasoned plan for 2026 (run-rate EPS ~$24.75, $1.5B planned in-force deployment). Overall, positive operational momentum and balance sheet strength outweigh the manageable and disclosed challenges, though some near-term uncertainty remains around in-force action timing and investment income recognition.
Q4-2025 Updates
Positive Updates
Record Quarterly and Full-Year Earnings
Q4 operating EPS of $7.75 (second consecutive record quarter) and record 2025 operating EPS for the year.
Return on Equity Above Target
Adjusted operating ROE (trailing 12 months, excluding notable items) of 15.7%, exceeding the intermediate-term target range of 13%–15%.
Substantial Increase in Value of In-Force Business
Value of in-force business margins increased by $6.6 billion, an 18% rise in 2025; over the past two years value increased by over $11 billion (~16% p.a.).
Strong Regional Performance
APAC pretax operating income (ex-notable items) up 18% for the year; EMEA pretax earnings (ex-notable items) up 35%; North America benefitted from Equitable block and in-force actions.
Capital Deployment and Balance Sheet Strength
Deployed $2.5 billion into in-force transactions in 2025; ended Q4 with estimated excess capital of $2.7 billion and next 12 months deployable capital of $3.4 billion.
Reinstated Share Buybacks and Capital Return Plan
Repurchased $50 million in Q4 (total $125 million since reinstatement) and targeting a 20%–30% total payout ratio (buybacks + dividends) over the intermediate term.
Premium Growth
Traditional premium growth of 7.4% year-to-date on a constant currency basis, reflecting momentum across North America, EMEA and APAC.
Investment Performance and Variable Investment Income
Variable investment income was about $48 million above expectations in Q4, supported by higher limited partnership income and repositioning of acquired portfolios.
In-Force Management Actions Contribution
In-force management actions produced favorable impacts: ~$75 million in 2023, ~$225 million in 2024 and ~$135 million in 2025; Q4 actions had a $95 million favorable impact.
Book Value Growth
Book value per share (excluding AOCI and certain embedded derivative impacts) increased to $165.50, representing a 10% compounded annual growth rate since 2021.
Negative Updates
Unfavorable Biometric Claims in Quarter
Economic claims experience was unfavorable by $51 million in Q4 with a corresponding unfavorable current period financial impact of $53 million; roughly half driven by U.S. group business.
U.S. Group Health Challenges and Exit Decision
Underperformance in U.S. excess medical/group health prompted full repricing (average ~40% rate increases mid-2025–Jan 2026) and a strategic decision to stop writing and not renew group health business; U.S. health care is ~ $400 million annual premium generating ~ $25 million pretax run-rate earnings.
Reduced Predictability of In-Force Actions
Management noted the timing and size of in-force management actions are highly unpredictable and expects a more limited financial impact from such actions in 2026 versus recent years.
Corporate and Other Losses
Corporate and Other reported an adjusted operating loss before tax of $54 million in Q4; expected to be roughly $50–$55 million per quarter in 2026, impacted by higher financing costs and general expenses.
Exposure to Real Estate/Alternative Income Recognition
2026 variable investment income assumption set at 7% (above 6% in 2025 but below long-term expectations of 10%–12%) primarily due to a muted environment for real estate sales where income recognition is realized.
Dependence on Continued Deployment and Execution
Intermediate-term EPS growth guidance (8%–10%) assumes ~ $1.5 billion of annual capital deployed into in-force transactions and continued successful execution; additional capital deployment and timing/ramp effects add uncertainty to year-to-year results.
Company Guidance
RGA’s guidance highlighted a 2025 run‑rate adjusted operating EPS of about $24.75 per share and reiterated intermediate‑term targets of 8%–10% annual EPS growth and a 13%–15% ROE (trailing 12‑month adjusted operating ROE was 15.7%); management assumes 7% variable investment income for 2026 (vs. 6% in 2025 and a long‑term 10%–12% expectation), a 2026 tax rate of 22%–23% (23.8% in Q4; 22.8% for full‑year 2025), and run‑rate corporate & other losses of about $50M–$55M per quarter. Capital plans call for ~$1.5B of in‑force transaction deployment in 2026, $400M to reduce financial leverage, opportunistic share buybacks (20%–30% total payout of after‑tax operating earnings target) with $50M repurchased in Q4 and $125M since buybacks reinstated, and ending Q4 excess capital of $2.7B (next‑12‑month deployable capital ~$3.4B). Other numeric highlights incorporated into guidance: Q4 operating EPS $7.75; in‑force value up $6.6B (18%) in 2025 and >$11B over two years (~16% p.a.); in‑force management actions contributed $95M in Q4 and $135M in 2025 (vs. $225M in 2024, $75M in 2023) but are expected to be more limited in 2026; Equitable transaction earnings were $60M–$70M in H2 2025 and are expected to be $160M–$170M in 2026; Q4 economic claims were unfavorable ~$51M (financial impact ~$53M) though since 2023 economic claims have been favorable ~$226M; and the firm expects the retrocession vehicle to be fully deployed by mid‑2026.

Reinsurance Group Financial Statement Overview

Summary
Solid fundamentals with meaningful multi-year revenue growth and improved 2025 profitability, supported by strengthening equity and improving leverage (debt-to-equity ~0.42). Key risk is business volatility: margins and cash flows have been notably lumpy year-to-year, including a large 2025 cash flow pullback versus an unusually strong 2024.
Income Statement
74
Positive
Revenue has grown meaningfully over the last several years (from ~$14.6B in 2020 to ~$22.8B in 2025), with a sharp acceleration in the latest year (2025 revenue growth of 2.339). Profitability also improved in 2025, with net income rising to ~$1.18B and net margin improving to ~5.2% (vs. ~3.3% in 2024). Offsetting this, margins have been volatile across the period (net margin ranging from ~2.8% to ~7.3%), and the 2025 growth rate appears unusually high versus prior years, suggesting results may be less predictable year-to-year.
Balance Sheet
78
Positive
The balance sheet shows moderate leverage for the sector, with debt-to-equity improving to ~0.42 in 2025 from higher levels in 2022–2024 (~0.47–0.62). Equity has strengthened materially (to ~$13.5B in 2025 from ~$7.1B in 2022), supporting balance-sheet resilience as assets expanded significantly. Return on equity is solid but not consistently rising (about ~8.8% in 2025 vs. ~9.9% in 2023), indicating profitability is adequate but still somewhat uneven.
Cash Flow
63
Positive
Cash generation is generally strong, with operating cash flow positive each year and free cash flow matching operating cash flow in the provided data (e.g., ~$4.09B in 2025). However, cash flow is notably volatile: operating/free cash flow fell in 2025 versus 2024 (free cash flow growth of -15.458) after an unusually high 2024 level (~$9.37B). Also, the provided operating cash flow coverage ratio is 0.0 throughout, limiting what can be concluded about cash coverage from the dataset.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue22.79B22.04B18.39B15.88B16.06B
Gross Profit5.79B2.49B2.33B1.57B1.85B
EBITDA1.95B1.33B1.46B947.00M1.57B
Net Income1.18B717.00M902.00M517.00M1.17B
Balance Sheet
Total Assets156.59B118.67B97.62B84.90B92.17B
Cash, Cash Equivalents and Short-Term Investments4.17B3.33B2.97B2.93B2.95B
Total Debt5.71B5.04B4.43B3.96B3.85B
Total Liabilities143.04B107.77B88.45B77.73B79.16B
Stockholders Equity13.46B10.82B9.08B7.08B13.01B
Cash Flow
Free Cash Flow4.09B9.37B4.04B1.32B4.16B
Operating Cash Flow4.09B9.37B4.04B1.34B4.18B
Investing Cash Flow-12.09B-12.54B-4.07B-5.69B-4.63B
Financing Cash Flow8.80B3.66B78.00M4.44B20.00M

Reinsurance Group Technical Analysis

Technical Analysis Sentiment
Negative
Last Price197.99
Price Trends
50DMA
207.29
Negative
100DMA
200.34
Negative
200DMA
195.55
Positive
Market Momentum
MACD
-2.92
Positive
RSI
34.16
Neutral
STOCH
20.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGA, the sentiment is Negative. The current price of 197.99 is below the 20-day moving average (MA) of 209.13, below the 50-day MA of 207.29, and above the 200-day MA of 195.55, indicating a neutral trend. The MACD of -2.92 indicates Positive momentum. The RSI at 34.16 is Neutral, neither overbought nor oversold. The STOCH value of 20.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RGA.

Reinsurance Group Risk Analysis

Reinsurance Group disclosed 37 risk factors in its most recent earnings report. Reinsurance Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Reinsurance Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
$2.83B4.9122.09%22.79%-5.17%
80
Outperform
$12.64B4.7024.24%0.57%-3.96%-48.08%
75
Outperform
$12.76B8.8310.61%2.37%8.62%-78.92%
73
Outperform
$12.98B11.389.48%1.76%2.10%19.23%
71
Outperform
$543.40M6.5911.10%5.83%-101.38%
71
Outperform
$2.38B5.5520.87%7.87%-4.68%
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RGA
Reinsurance Group
197.99
3.23
1.66%
EG
Everest Group
316.02
-34.50
-9.84%
GLRE
Greenlight Capital Re
15.99
2.51
18.62%
RNR
Renaissancere Holdings
290.73
52.50
22.04%
SPNT
SiriusPoint
20.38
4.13
25.42%
HG
Hamilton Insurance Group, Ltd. Class B
28.55
8.61
43.17%

Reinsurance Group Corporate Events

Business Operations and StrategyExecutive/Board Changes
Reinsurance Group Adds Peter Babej to Board
Positive
Mar 19, 2026

On March 19, 2026, Reinsurance Group of America announced that its board had appointed former Citigroup executive Peter Babej as a director, effective April 1, 2026, for a term running until the 2026 annual meeting of shareholders. The appointment expands the board to 12 members and places a seasoned global financial services specialist at the heart of the reinsurer’s governance.

Babej, 62, brings more than three decades of experience across banking, insurance, and financial advisory, including roles as CEO of Citi Asia Pacific and Chairman and Interim Head of Banking before his 2024 retirement. His background in leading major strategic initiatives, particularly in Asia-Pacific operations and financial institutions, is expected to bolster RGA’s international expansion efforts and support its long-term strategic agenda.

RGA highlighted that Babej has no material related-party transactions with the company and that there were no special arrangements underpinning his appointment to the board. He will receive standard non-employee director compensation, and while he has not yet been assigned to specific board committees, his appointment signals RGA’s focus on strengthening expertise in capital markets and global insurance as it competes in the life and health reinsurance sector.

The most recent analyst rating on (RGA) stock is a Buy with a $264.00 price target. To see the full list of analyst forecasts on Reinsurance Group stock, see the RGA Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
Reinsurance Group Completes $400 Million Subordinated Debt Offering
Positive
Mar 3, 2026

On March 3, 2026, Reinsurance Group of America completed a $400 million public offering of 6.375% Fixed-Rate Reset Subordinated Debentures due 2056, issued at par under its existing shelf registration and indenture structure. The unsecured notes, which are subordinated to senior and secured debt and rank pari passu with several of its other hybrid capital instruments, will pay semi-annual interest and may be redeemed at par during specified reset-related windows, at a make-whole price otherwise, or upon defined tax, regulatory capital, or rating agency events.

The transaction generated approximately $396 million in net proceeds before expenses, which the company plans to use for general corporate purposes, including potential refinancing of existing obligations. By adding a new long-dated subordinated layer that is effectively junior to subsidiary liabilities yet senior to certain junior securities, RGA further diversifies and extends its capital structure, reinforcing financial flexibility and maintaining established banking and underwriting relationships with major dealers involved in its credit facilities and capital markets activities.

The most recent analyst rating on (RGA) stock is a Hold with a $223.00 price target. To see the full list of analyst forecasts on Reinsurance Group stock, see the RGA Stock Forecast page.

Business Operations and StrategyStock BuybackDividendsFinancial Disclosures
Reinsurance Group posts strong Q4 2025 earnings results
Positive
Feb 5, 2026

On February 5, 2026, Reinsurance Group of America reported strong fourth-quarter and full-year 2025 results, with quarterly net income available to shareholders rising to $463 million, or $6.97 per diluted share, from $148 million, or $2.22 per diluted share, a year earlier, and adjusted operating income climbing to $515 million, or $7.75 per diluted share. For full-year 2025, net income increased to $1.18 billion, or $17.69 per diluted share, while adjusted operating income reached $1.52 billion, or $22.72 per diluted share, supported by robust investment performance, favorable foreign currency effects, and capital deployment that included $2.5 billion into in-force block transactions and $125 million of share repurchases; the board also declared a regular quarterly dividend of $0.93 per share effective February 3, 2026, underscoring confidence in the company’s capital position and reinforcing its trajectory toward intermediate-term financial targets and continued strong returns for shareholders.

The most recent analyst rating on (RGA) stock is a Hold with a $205.00 price target. To see the full list of analyst forecasts on Reinsurance Group stock, see the RGA Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 20, 2026